Portfolios - Investment - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

TinoMed

2026 - 08 - 01

TinoMed (688806.SH) is a global-facing innovative biopharmaceutical company dedicated to developing alternative therapies for blood products. On July 21, 2026, TinoMed was listed on the STAR Market (Shanghai Stock Exchange's Sci-Tech Innovation Board). EFUNG Capital invested in TinoMed in 2023.

Chipscreen Biosciences

2018 - 10 - 29

Epidaza (Chidamide) is the first marketed innovative drug developed by a Chinese pharmaceutical company. As an oral HDAC inhibitor, Epidaza targets recurrent peripheral T cell lymphoma. Meanwhile, it can also treat other hematological cancer, solid tumor and even HIV combined with other drugs. Multiple clinical trials are conducted in the U.S., Japan, China and Taiwan.

Ascentage Pharma

2018 - 10 - 29

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Its expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosisor programmed cell death. There are seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).